Indication for allo-SCT in FLT3-ITDmut AML is contingent on multiple factors, such as allelic burden, concurrent mutations such as NPM1, MRD status, and prior use of FLT3i, as well as unique variables pertaining to the recipient, donor availability, and graft specifics. The gene discussed is NPM1; the disease is acute myeloid leukemia.